Tag Archives: CEO Angelos Stergiou

Angelos Stergiou Notes Benefits of Galinpepimut-S Following Autotransplantation

SELLAS Life Sciences Group’s Phase II clinical trials of galinpepimut-S, an immunotherapeutic anti-cancer treatment, have illustrated significant benefits for those patients who have utilized it following autotransplantation with high-risk multiple myeloma, particularly those with an adverse cytogenetic profile.  “We are … Continue reading

Posted in Angelos Stergiou | Tagged , , | Leave a comment

Angelos Stergiou Thrilled With Phase II Trial Results

Dr. Angelos Stergiou values SELLAS’ appointment of Dr. Jonathan Eckard to its executive team in light of Eckard’s experience as Director and Senior Biotechnology Analyst for Barclays, a universal bank with operations in over 50 countries and territories and 48 … Continue reading

Posted in Angelos Stergiou | Tagged , , , | Leave a comment

Angelos Stergiou Announces Dr. Jonathan Eckard Appointment

SELLAS Life Sciences Group specializes in biopharmaceuticals for late stage cancer immunotherapies which cover a significant range of indication for cancer.  SELLAS recently appointed Dr. Jonathan Eckard to their team as a Chief Business and Strategy Officer.  Dr. Eckard has … Continue reading

Posted in Angelos Stergiou | Tagged , , , | Leave a comment